Drugs / Gamma Hydroxybutyrate
Gamma Hydroxybutyrate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00058955 | Aug 2003 → Mar 2005 | substance abuse | Orphan Medical | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07596342 | Jun 2026 → Oct 2027 expected | sleep disorder | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04224246 | Feb 2020 → Feb 2023 | — | Poitiers University Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02342366 | Feb 2012 → Nov 2014 | autism, bipolar disorder, major depressive disorder | University of Zurich | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04508166 Comparator | Oct 2021 → Jan 2022 | post-traumatic stress disorder | Psychiatric University Hospital, Zurich | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gamma-hydroxybutyrate | “Gamma-hydroxybutyrate (GHB) is currently used for several sleep disorders, such as narcolepsy” NCT07596342 ↗3“gamma-Hydroxybutyrate (GHB) has prosocial and prosexual effects in healthy male participants” NCT02342366 ↗ |
| Known as | gamma-hydroxybutyric acid | “The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid by comparing its physiological, behavioral and subjective effects with those of...” NCT00058955 ↗ |
| Known as | Gamma-OH | “Intravenous GHB (Gamma-OH) will be administered at a dose of 15 mg/kg as induction over 20 minutes” NCT07596342 ↗ |
| Known as | GHB | “The purpose of this study is to learn more about the effects of gamma-hydroxybutyric acid (GHB) by comparing its physiological, behavioral and subjective effects with those of...” NCT00058955 ↗ |
| Action | Activate | “Gamma-hydroxybutyrate (GHB; or sodium oxybate) is an endogenous GHB-/gamma-aminobutyric acid B receptor agonist.” PMID 31504554 ↗ Oct 2019 |
| Modality | Small molecule | “Gammahydroxybutyrate (GHB) is an endogenous short-chain fatty acid” NCT02342366 ↗ |
| Route | Oral | “GHB (20 mg/kg p.o.) was tested in 16 healthy males” NCT02342366 ↗ |